A Study of Experimental Medication BMS-986235 in Healthy Subjects

Randomized, Double-Blind, Placebo-Controlled Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BMS-986235 in Healthy Subjects

This is a study of experimental medication BMS-986235 in healthy subjects.

Inclusion Criteria:

• Patients must be normal healthy volunteers as determined by no clinically significant deviations in medical history, physical examination, ECGs, vital signs, and clinical laboratory determinations
• Patients must have a body mass index (BMI) of 18 - 30 mg/kg2, inclusive

Exclusion Criteria:

• Patients that are pregnant
• Patient with any significant acute or chronic medical illness
• Patient with a current or recent (within 3 months of study treatment administration) gastrointestinal disease that could affect absorption
• Patient with any surgery within 12 weeks of study treatment administration
• Patient with any gastrointestinal surgery that could impact upon the absorption of study drug
• Patient who donated blood to a blood bank or in a clinical study (except a screening visit) within 12 weeks of study drug administration (within 2 weeks for plasma only)
• Patient who received a blood transfusion within 12 weeks of study drug administration

Other protocol defined inclusion/exclusion criteria apply